{"id":"treatment-of-encorafenib-binimetinib-cetuximab","rwe":[],"tags":[],"phase":"preclinical","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"active","trials":["NCT05203172","NCT02928224","NCT03693170","NCT04800822"],"_pubmed":{"count":0,"papers":[]},"_rxnorm":{"forms":[]},"aliases":[],"patents":[],"pricing":[],"allNames":"treatment of encorafenib & binimetinib & cetuximab","offLabel":[],"timeline":[{"date":"2019","type":"neutral","milestone":"Phase 3 Initiated","description":"Phase 3 trial (Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-) — BRAF V600E-mutant Metastatic Colorectal Cancer"},{"date":"2020","type":"neutral","milestone":"Phase 2 Initiated","description":"Phase 2 trial (Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal ) — BRAF V600E-mutant Metastatic Colorectal Cancer"},{"date":"2024","type":"negative","milestone":"Phase 1 Initiated","description":"Phase 1 trial (PF-07284892 in Participants With Advanced Solid Tumors) — Solid Tumor. Trial terminated early."},{"date":"2029","type":"neutral","milestone":"Phase 4 Initiated","description":"Phase 4 trial (The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib fo) — Solid Tumors"}],"aiSummary":"Encorafenib, Binimetinib, and Cetuximab are being studied in clinical trials for the treatment of BRAF V600E mutated or pMMR localized colorectal cancer. Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor, which works by blocking the activity of the EGFR protein.","brandName":"Treatment of Encorafenib & Binimetinib & Cetuximab","companyId":"pfizer","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"Monoclonal antibody","drugClass":"Encorafenib will be administered on a 300 mg QD schedule and binimetinib will be administered on a 4","explanation":"","oneSentence":"Encorafenib will be administered on a 300 mg QD schedule and binimetinib will be administered on a 4","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Pfizer Inc.","competitors":[],"genericName":"treatment-of-encorafenib-binimetinib-cetuximab","indications":{"approved":[],"offLabel":[],"pipeline":[{"name":"Solid Tumors","phase":"preclinical","trialId":"","patients":null,"diseaseId":"oncology","trialName":"","primaryEndpoint":"","expectedCompletion":""}]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05203172","phase":"PHASE4","title":"The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-07-05","conditions":"Solid Tumors","enrollment":46,"completionDate":"2029-07-31","primaryEndpoint":"Number of participants with adverse events leading to permanent discontinuation of study intervention"},{"nctId":"NCT03803553","phase":"PHASE3","title":"Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-04-16","conditions":"Metastatic Colon Cancer, Stage III Colon Cancer","enrollment":400,"completionDate":"2027-12","primaryEndpoint":"Disease-free survival (DFS)"},{"nctId":"NCT05510895","phase":"PHASE2","title":"Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2022-09-01","conditions":"Colorectal Cancer, Colon Cancer, BRAF V600E","enrollment":2,"completionDate":"2025-01-31","primaryEndpoint":"Tumor regression grade (TRG)"},{"nctId":"NCT04800822","phase":"PHASE1","title":"PF-07284892 in Participants With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Pfizer","startDate":"2021-03-17","conditions":"Solid Tumor","enrollment":53,"completionDate":"2024-06-19","primaryEndpoint":"Part 1 and Part 2- Number of participants with dose limiting toxicities (DLTs)"},{"nctId":"NCT06207656","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","startDate":"2024-04-16","conditions":"Colorectal Cancer","enrollment":70,"completionDate":"2029-04-01","primaryEndpoint":"Efficacy of cetuximab in combination with encorafenib plus binimetinib as induction therapy for the treatment of BRAF-V600E mutated MSS aCRC to perform radical treatment of the primary and/or metastas"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"_hyperScrapedAt":"2026-03-27T18:42:30.246209","crossReferences":{"chemblId":"CHEMBL1201577"},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"firstApprovalDate":"","_hyperScrapedFields":["patents","pricing","trials","ema","mhra","who","safety-signals","recalls","dailymed","pubmed","drugbank","chembl","rxnorm","medicare","pharmgkb","sec","company-ir","wikipedia","drug-website","google"],"companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Monoclonal antibody","enrichmentLevel":3,"visitCount":7,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}